- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05738382
Efficacy and Safety of BG2109 During Controlled Ovarian Hyperstimulation in Female Subjects Undergoing ART Procedures
July 25, 2023 updated by: Bio Genuine (Shanghai) Biotech Co., Ltd.
A Randomized, Double-blind, Open for Active Comparator, Parallel, Multi-center Phase II Study to Explore the Efficacy, Safety and Tolerability of BG2109 Compared With Cetrorelix During COH in Female Subjects Undergoing ART Procedures
To explore the optimal effective daily dose of BG2109 to suppress premature luteinizing hormone (LH) surge during COH in female subjects undergoing ART procedures.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Detailed Description
This study is a randomized, double-blind, open for active comparator, parallel, multi-center phase II dose-finding clinical study to explore the efficacy, safety and tolerability of different doses of BG2109 compared with Cetrorelix during Controlled Ovarian Hyperstimulation (COH) in Chinese female subjects undergoing Assisted Reproductive Technology (ART) procedures.
Study Type
Interventional
Enrollment (Estimated)
240
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jing Zhao
- Phone Number: 021-58590032
- Email: Jing.zhao@Biogenuine.con
Study Locations
-
-
-
Changsha, China
- Site No5
-
Guangzhou, China
- Site No7
-
Haikou, China
- Site No9
-
Hangzhou, China
- Site No4
-
Hohhot, China
- Site No8
-
Linyi, China
- Site No6
-
Shenyang, China
- Site No10
-
Tianjin, China
- Site No11
-
Wuhan, China
- Site No3
-
Zhengzhou, China
- Site No2
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 39 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Married infertile women aged 20 to 39 years (both inclusive), who are diagnosed with tubal infertility, unexplained infertility, grade I-II endometriosis, or spouses diagnosed with male factor infertility, who meet the criteria for IVF and/or ICSI) using fresh or frozen semen from the male spouse or sperm donor
- BMI 18-25 kg/m2 (both inclusive), body weight range 45-80kg (both inclusive)
- Subjects must have regular menstrual cycles, specifically defined as ≥25 days, ≤35 days.
- The serum sex hormone levels during the screening period must be performed in the early follicular phase, and the basal serum follicle-stimulating hormone (FSH) <10 IU/L, LH, estradiol(E2), prolactin(PRL),testosterone(T) levels are within the laboratory normal range, or the investigator considers them as abnormal but not clinically significant
- The subject is clinically assessed and agree to undergo fresh cycle embryo transfer in the first IVF-ET/ ICSI-Embryo Transfer(ET) cycle, with a maximum of two embryos transferred.
- Within 1 year before randomization, the presence of bilateral ovaries is clearly visible on transvaginal ultrasonography with no significant abnormalities, and appendages are normal. Both ovaries must be available for oocyte retrieval
- Subjects must sign the Informed Consent Form (ICF) and be willing and able to abide by the protocol-specified study procedures
Exclusion Criteria:
- Those who have undergone 2 or more COH of IVF/ICSI-ET before screening, but have not achieved clinical pregnancy.
- Those with previous IVF or ART failure due to sperm/fertilization problems whose related medical condition has not been improved.
- Either subjects or their spouses or both of them are known to carry abnormal chromosomal structures, or patients known to have single-gene genetic diseases or serious diseases with genetic susceptibility requiring Preimplantation Genetic Diagnosis(PGD) before embryo transfer.
- Those with high risk of ovarian hyperstimulation syndrome(OHSS)
- Those with low ovarian function at screening, with at least one of the following: poor ovarian response in the past; less than 6 antral follicles (AFC) with a diameter of < 10 mm seen on bilateral ovary transvaginal ultrasonography at Day2-3 of menstrual cycle; anti-mullerian hormone(AMH) < 1.1 ng/ml.
- Subjects who used gonadotropins for ovarian stimulation or drugs that affect ovarian function within 30 days prior to screening.
- Subjects with abnormal thinprep cytology test(TCT) results that are judged by the investigator as clinically significant and require treatment within 6 months before screening.
- As judged by the investigator, subjects with clinically significant gynecological diseases at screening
- Those previously or prior randomization suffering from the cancer of uterine, ovarian, breast or hypothalamus or pituitary gland.
- Those with a positive serum β-hCG test result at the screening visit or the visit on Day 1 of ovarian stimulation.
- During COH, LH ≥10 U/L, and the LH level was 2.5 times higher than the baseline value before D0 (inclusive).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BG2109 75mg
oral, once a day
|
oral administration once daily
|
Experimental: BG2109 150mg
oral, once a day
|
oral administration once daily
|
Experimental: BG2109 200mg
oral, once a day
|
oral administration once daily
|
Active Comparator: Cetrorelix
0.25mg, Subcutaneous injection, once a day
|
0.25 mg, Subcutaneous injection once daily.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Suppression rate of premature LH surge from the treatment of investigational medicinal products(IMP) until the day of human chorionic gonadotropin(hCG) injection
Time Frame: Through the whole period of administration of IMP,about 5-10 days
|
LH ≥ 10 IU/L
|
Through the whole period of administration of IMP,about 5-10 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ongoing pregnancy rate
Time Frame: At 10 weeks post-embryo transfer
|
ongoing pregnancy is defined as at least embryo with heartbeat at 10 weeks post-embryo transfer
|
At 10 weeks post-embryo transfer
|
The number of oocytes obtained on the day of oocyte retrieval
Time Frame: During the surgery of the oocyte retrieval
|
During the surgery of the oocyte retrieval
|
|
Clinical pregnancy rate
Time Frame: On 30-37 days after embryo transfer
|
clinical pregnancy is defined as the presence of at least one gestational sac in or outside the uterus during 30-37 days after embryo transfer
|
On 30-37 days after embryo transfer
|
Adverse drug events
Time Frame: Through study completion, around 45 weeks.
|
Through study completion, around 45 weeks.
|
|
Pharmacokinetics(PK) endpoints
Time Frame: On the morning of the Second and Third day of BG2109 administration, and the day of hCG injection(about 5-10days after BG2109 administration)
|
Plasma concentration of BG2109
|
On the morning of the Second and Third day of BG2109 administration, and the day of hCG injection(about 5-10days after BG2109 administration)
|
Pharmacodynamics(PD) endpoints
Time Frame: 30 minutes before the administration of BG2109 every morning through the whole period of IMP administration,about 5-10 days
|
estradiol(E2), luteinizing hormone (LH) and progesterone (P) concentrations at each time point
|
30 minutes before the administration of BG2109 every morning through the whole period of IMP administration,about 5-10 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Xiaoyan Liang, Sixth Affiliated Hospital, Sun Yat-sen University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
August 1, 2023
Primary Completion (Estimated)
June 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
January 28, 2023
First Submitted That Met QC Criteria
February 21, 2023
First Posted (Actual)
February 22, 2023
Study Record Updates
Last Update Posted (Actual)
July 27, 2023
Last Update Submitted That Met QC Criteria
July 25, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Ovarian Hyperstimulation Syndrome
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Reproductive Control Agents
- Fertility Agents, Female
- Fertility Agents
- Cetrorelix
Other Study ID Numbers
- BG2109-AC-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Assisted Reproductive Technology
-
Merck KGaA, Darmstadt, GermanyMerck Serono GmbH, Germany; Merck B.V., Netherlands; Merck A.E., Greece; Merck... and other collaboratorsCompletedAssisted Reproductive Techniques | Reproductive Technology, AssistedItaly, Russian Federation, United Kingdom, Germany, Poland, Finland, Slovakia, Netherlands, Denmark, France, Greece
-
Nanjing Medical UniversityCompletedAssisted Reproductive TechnologyChina
-
Tu Du HospitalRecruitingAssisted Reproductive TechnologyVietnam
-
Royal Fertility Center, EgyptHawaa Fertility CenterCompletedAssisted Reproductive TechnologyEgypt
-
khalid abd aziz mohamedWithdrawnDiagnostic Value of Sperm DNA Fragmentation and Sperm Morphology for Assisted Reproduction TreatmentAssisted Reproductive TechnologyEgypt
-
Jinling Hospital, ChinaCompletedUltrasonography | Assisted Reproductive TechnologyChina
-
Chengdu University of Traditional Chinese MedicineCompletedFailure After Assisted Reproductive TechnologyChina
-
Chengdu University of Traditional Chinese MedicineCompletedFailure After Assisted Reproductive TechnologyChina
-
University Hospital, Clermont-FerrandRecruitingFertility | Assisted Reproductive Technology | Vitrification | Egg DonorFrance
-
Women's Hospital School Of Medicine Zhejiang UniversityNot yet recruitingFertility Disorders | Assisted Reproductive Technology | Offspring Health
Clinical Trials on BG2109
-
Bio Genuine (Shanghai) Biotech Co., Ltd.RecruitingEndometriosis | Moderate to Severe Endometriosis-associated PainChina
-
Bio Genuine (Shanghai) Biotech Co., Ltd.RecruitingUterine Fibroids | Heavy Menstrual BleedingChina